Notre Dame
Claris GenomiX Seeks Commercialization Partners for Cancer Subtyping Tests, Starting With CRC
Premium
The University of Notre Dame spinout has developed molecular subtyping tests for colorectal and other cancers, and seeks partners to bring them to the clinic.
The amplification-free platform uses miRNAs in its ion-exchange platform to return results in less than 30 minutes.
Notre Dame Team Wins $2.9M NIH Grant for ExRNA Analysis Platform
The platform is designed to isolate exosomes from blood, then release their extracellular RNA cargo for analysis as biomarkers for diseases including cancer.